Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of an orally administered dose of TW-012R in patients
with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo
group as a control. In addition, long-term safety will be examined in an open-label extension
trial.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyoto University
Collaborators:
Asakayama General Hospital Asakayama Hospital Kawasaki Medical School Hospital Mie University Nagoya City University Hospital Osaka University Time Therapeutics, Inc. Tokushima University Tokyo Metropolitan Geriatric Medical Center Towa Pharmaceutical Co.,Ltd.